ARTICLE | Company News
Idenix, Merck deal
September 1, 2014 7:00 AM UTC
Merck completed its tender offer to acquire Idenix for $24.50 per share in cash, or about $3.9 billion (see BioCentury, June 16). ...
Merck completed its tender offer to acquire Idenix for $24.50 per share in cash, or about $3.9 billion (see BioCentury, June 16). ...